Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat

被引:35
作者
Yu, H [1 ]
Lewander, T [1 ]
机构
[1] UPPSALA UNIV,DEPT PSYCHIAT,S-75017 UPPSALA,SWEDEN
关键词
8-OH-DPAT; 5-HT1A receptors; enantiomers; drug concentration; brain; rat;
D O I
10.1016/S0924-977X(96)00395-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Racemic 8-OH-DPAT, (R,S)-8-hydroxy-2-(di-n-propylamino)tetralin, has become the prototype 5-HT1A receptor agonist. The enantiomers of 8-OH-DPAT have similar affinities to the 5-HT1A receptor, but the (R)-enantiomer is a full agonist, whereas the (S)-enantiomer is a partial agonist. This communication describes the dose- and time-response relationships of behavioural (5-HT behavioural syndrome, cage-leaving response), physiological (body temperature) and biochemical (5-HT turnover, 5-hydroxytryptophan accumulation) effects of (R)-8-OH-DPAT in rats. A high-performance liquid chromatography (HPLC)-UV method for determination of plasma and brain concentrations of (R)-8-OH-DPAT was developed, permitting studies of the pharmacokinetics of the drug. The concentrations of 8-OH-DPAT in brain were several fold higher than in plasma, and there were large variations in (R)-8-OH-DPAT concentrations between brain regions (highest in the hippocampus). (R)-8-OH-DPAT peaked in plasma at 5 min and in brain at 15 min after subcutaneous administration. The 5-HT1A behavioural syndrome peaked within 5 min after administration and disappeared after 30 min, when brain concentrations were still high. The hypothermic and biochemical responses developed gradually and were maximal at 45-60 min post injection, when both plasma and brain concentrations were declining. Thus, there was not a simple relationship between the kinetics and the dynamics of(R)-8-OH-DPAT. These results prompt further studies on the pharmacokinetics of 8-OH-DPAT within the central nervous system. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:165 / 172
页数:8
相关论文
共 29 条
[1]   8-HYDROXY-2-(DI-NORMAL-PROPYLAMINO)TETRALIN, A NEW CENTRALLY ACTING 5-HYDROXYTRYPTAMINE RECEPTOR AGONIST [J].
ARVIDSSON, LE ;
HACKSELL, U ;
NILSSON, JLG ;
HJORTH, S ;
CARLSSON, A ;
LINDBERG, P ;
SANCHEZ, D ;
WIKSTROM, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (08) :921-923
[2]  
BJORK L, 1989, J MED CHEM, V32, P779
[3]   SIMULTANEOUS MEASUREMENT OF TYROSINE AND TRYPTOPHAN HYDROXYLASE-ACTIVITIES IN BRAIN IN-VIVO USING AN INHIBITOR OF AROMATIC AMINO-ACID DECARBOXYLASE [J].
CARLSSON, A ;
ATACK, CV ;
LINDQVIST, M ;
KEHR, W ;
DAVIS, JN .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1972, 275 (02) :153-+
[4]  
CORNFIELD LJ, 1991, MOL PHARMACOL, V39, P780
[5]  
DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1
[6]  
GOZLAN H, 1988, J PHARMACOL EXP THER, V244, P751
[7]   5-OXYGENATED N-ALKYL-2-AMINO-1-METHYLTETRALINS AND N,N-DIALKYL-2-AMINO-1-METHYLTETRALINS - EFFECTS OF STRUCTURE AND STEREOCHEMISTRY ON DOPAMINE-D2-RECEPTOR AFFINITY [J].
GROL, CJ ;
NORDVALL, G ;
JOHANSSON, AM ;
HACKSELL, U .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1991, 43 (07) :481-485
[8]   [H-3]8-HYDROXY-2-(DI-NORMAL-PROPYLAMINO)TETRALIN BINDING TO PRESYNAPTIC AND POSTSYNAPTIC 5-HYDROXYTRYPTAMINE SITES IN VARIOUS REGIONS OF THE RAT-BRAIN [J].
HALL, MD ;
ELMESTIKAWY, S ;
EMERIT, MB ;
PICHAT, L ;
HAMON, M ;
GOZLAN, H .
JOURNAL OF NEUROCHEMISTRY, 1985, 44 (06) :1685-1696
[9]   8-HYDROXY-2-(DI-NORMAL-PROPYLAMINO)TETRALIN, 8-OH-DPAT, A POTENT AND SELECTIVE SIMPLIFIED ERGOT CONGENER WITH CENTRAL 5-HT-RECEPTOR STIMULATING ACTIVITY [J].
HJORTH, S ;
CARLSSON, A ;
LINDBERG, P ;
SANCHEZ, D ;
WIKSTROM, H ;
ARVIDSSON, LE ;
HACKSELL, U ;
NILSSON, JLG .
JOURNAL OF NEURAL TRANSMISSION, 1982, 55 (03) :169-188